DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

Johnson & Johnson (NYSE: JNJ)

100.14 -2.24 (-2.19%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

JNJ $100.14 -2.19%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $101.58
Previous Close $102.38
Daily Range $100.09 - $102.00
52-Week Range $86.09 - $109.49
Market Cap $280.3B
P/E Ratio 17.15
Dividend (Yield) $2.80 (2.7%)
Ex-Dividend Date
Dividend Pay Date
02/20/15
03/10/15
Volume 10,671,872
Average Daily Volume 9,174,335
Current FY EPS $6.21

Sector

Healthcare

Industry

Drugs

Johnson & Johnson (JNJ) Description

A vast and diverse health care giant, Johnson & Johnson strives to help people get well through its consumer products, pharmaceuticals, and medical devices. Website: http://www.jnj.com/

News & Commentary Rss Feed

3 Principles of Successful Dividend Investing

Dividend investing is one of the best ways to build wealth while keeping your money safe. But how do you know which stocks to choose?

Big Pharma: An Up-Close Look at One Key Player

Industry Focus zooms in on restructuring, new drugs, and possible threats for pharma giant Novartis.

3 Small-Cap Biotech Stocks That Could Be Top Stocks in 2015

Portola Pharmaceuticals, Ophthotech, and Achillion Pharmaceuticals have catalysts ahead that could make them top stocks to watch this year.

Gilead Sciences' Future in 3 Simple Slides

Three reasons that Gilead Sciences' future may prove to be bright.

The Golden Age of Dividend Investing Is Dead

Dividend stocks may be the heart and soul of many retirement portfolios, but income investing has taken a sharp right turn since the mid 1990s. Find out why quality dividends today are so hard to find.

Obamacare Hurdles Lowered Expectations, But Has 3 Major Questions Left Unanswered

The latest update from the Department of Health and Human Services shows that Obamacare enrollment has easily surpassed targets. But, it's not time to start celebrating just yet as Obamacare has three big questions still to be answered.

Pharmacyclics Up on Imbruvica Label Expansion in the U.S. - Analyst Blog

Abbott Reports Solid Q4 Results On Growth Across Divisions

Protalex Aiming At Rheumatoid Arthritis Market With A Much Cheaper Price Tag

One Way Johnson & Johnson Can Unlock At Least 25% Upside

See More JNJ News...

JNJ's Top Competitors

JNJ $100.14 (-2.19%)
Current stock: JNJ
PFE $31.25 (-1.82%)
Current stock: PFE
MRK $60.28 (-2.92%)
Current stock: MRK
BSX $14.81 (-0.27%)
Current stock: BSX